Yale University School of Medicine
Welcome,         Profile    Billing    Logout  
 408 Trials 
515 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Woods, Scott
NCT04262401: Promoting Healthy Habits in Metabolic Syndrome

Recruiting
N/A
424
US
Standard health coaching, Habit-focused health coaching
Habit Design, University of Washington, TriHealth Inc.
Metabolic Syndrome
04/24
12/24
Hochster, Howard S
COMPANION-002, NCT05506943: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers

Active, not recruiting
2/3
150
US
CTX-009, Paclitaxel
Compass Therapeutics
Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
07/25
12/25
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
QUIC, NCT06048133: Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers

Recruiting
2
39
US
Gemcitabine, Cisplatin, Zimberelimab, AB122, Quemliclustat, AB680
Nataliya Uboha, Arcus Biosciences, Inc., Gilead Sciences, University of Wisconsin, Madison
Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer
01/25
07/25
NCT05167409: A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer

Active, not recruiting
2
48
US
Evorpacept (ALX148), evorpacept, Cetuximab, Erbitux, Pembrolizumab, Keytruda
University of Colorado, Denver, ALX Oncology Inc., Merck Sharp & Dohme LLC, Eli Lilly and Company, Criterium, Inc., Academic GI Cancer Consortium (AGICC)
Microsatellite Stable Metastatic Colorectal Cancer
12/25
03/26
The AB7 Trial, NCT04829383: A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma

Active, not recruiting
2
50
US
Atezolizumab, Tecentriq, Bevacizumab, Avastin
Howard S Hochster, Genentech, Inc., Rutgers Cancer Institute of New Jersey
Unresectable Hepatocellular Carcinoma
10/24
10/25
NCT04169347: FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer

Active, not recruiting
2
27
US
Oxaliplatin, Irinotecan, Leucovorin, Panitumumab
Criterium, Inc., Amgen
Colorectal Cancer Metastatic
12/24
01/25
LoRusso, Patricia M
CBX-12-101, NCT04902872: Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Active, not recruiting
1/2
130
US
CBX-12
Cybrexa Therapeutics
Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer, Colorectal Cancer, Pancreas Cancer, Appendix Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Esophagus Cancer, Urothelial Carcinoma, Sarcoma
01/25
03/25
EVICTION, NCT04243499 / 2019-003847-31: First-in-Human Study of ICT01 in Patients With Advanced Cancer

Checkmark Data from EVICTION study in combination with Keytruda for solid tumor at ESMO 2022
Sep 2022 - Sep 2022: Data from EVICTION study in combination with Keytruda for solid tumor at ESMO 2022
Recruiting
1/2
150
Europe, US
IV ICT01
ImCheck Therapeutics, ImCheck Therapeutics, Inc.
Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer
06/25
12/25
NCT03917381 / 2018-003402-63: GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Active, not recruiting
1/2
429
Europe, US, RoW
Acasunlimab, GEN1046, DuoBody®-PD-L1x4-1BB, Acasunlimab in combination with docetaxel (in a single expansion cohort), Acasunlimab in combination with pembrolizumab (in a separate expansion cohort), Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
Genmab, BioNTech SE
Solid Tumors, Non-small Cell Lung Cancer, Urothelial Carcinoma, Endometrial Carcinoma, Triple Negative Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Cervical Cancer
02/26
02/26
NCT04875806: A Safety and Tolerability Study of NC762 in Subjects with Advanced or Metastatic Solid Tumors

Terminated
1/2
40
US
NC762
NextCure, Inc.
Advanced or Metastatic Solid Tumors, Ovarian Cancer, Non-small Cell Lung Cancer, Breast Cancer
01/24
01/24
ABOYA-119, NCT04905914: Study of ATRN-119 in Patients with Advanced Solid Tumors

Recruiting
1/2
132
US
ATRN-119
Aprea Therapeutics
Advanced Solid Tumor
12/24
06/25
GV20-0251-100, NCT05669430: A Study of GV20-0251 Monotherapy and GV20-0251 in Combination with Pembrolizumab in Participants with Solid Tumor Malignancies

Recruiting
1/2
365
US
GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®], MK-3475
GV20 Therapeutics, Merck Sharp & Dohme LLC
Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, PMMR/MSS Adenocarcinoma of the Colon or Rectum, Cutaneous Melanoma, Non-Small Cell Lung Cancer
12/26
09/27
Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Recruiting
1/2
374
Europe, Canada, Japan, US, RoW
Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil
Takeda, Takeda Development Center Americas, Inc. (TDC Americas)
Solid Neoplasms
01/26
01/26
NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
49
Europe, Japan, US, RoW
TAK-981, Pembrolizumab
Takeda, Takeda Development Center Americas, Inc.
Advanced or Metastatic Solid Tumors
11/25
11/25
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
PC14586, rezatapopt, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer
03/26
07/26
NCT00600496: A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Checkmark P1 data
Mar 2012 - Mar 2012: P1 data
Active, not recruiting
1
140
US
AZD6244, ARRY-142886, Dacarbazine, Erlotinib, Docetaxel, Taxotere®, Temsirolimus
AstraZeneca
Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer, Colon Neoplasms, Lung Cancer, Melanoma, Kidney Cancer
08/10
12/24
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Recruiting
1
475
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
GlaxoSmithKline
Neoplasms
08/25
02/27
NCT04237649: KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

Terminated
1
77
Europe, Canada, Japan, US, RoW
KAZ954, PDR001, NIR178, NZV930
Novartis Pharmaceuticals
Solid Tumors
09/23
09/23
NCT04417465: First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

Active, not recruiting
1
101
Europe, Japan, US, RoW
ABBV-CLS-579, PD-1 inhibitor, VEGFR TKI
AbbVie, Calico Life Sciences LLC
Advanced Solid Tumors Cancer
05/26
05/26
NCT04777994: A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

Recruiting
1
248
Europe, Japan, US, RoW
ABBV-CLS-484, Programmed Cell Death-1 (PD-1) Inhibitor, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)
AbbVie, Calico Life Sciences LLC
Advanced Solid Tumor Cancer
08/25
10/26
NCT03522142: A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

Active, not recruiting
1
84
Europe, US
INCB081776, INCMGA00012, retifanlimab
Incyte Corporation
Advanced Solid Tumors
04/25
04/25
AURELIO-03, NCT04234113: Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Terminated
1
115
Europe, US, RoW
Nanrilkefusp alfa, SOT101, SO-C101, RLI-15, Pembrolizumab, KEYTRUDA®
SOTIO Biotech AG, SOTIO Biotech a.s.
Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Melanoma, Merkel Cell Carcinoma, Skin Squamous Cell Carcinoma, Microsatellite Instability High, Triple Negative Breast Cancer, Mesothelioma, Thymic Cancer, Cervical Cancer, Biliary Tract Cancer, Hepatocellular Carcinoma, Ovarian Cancer, Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Anal Cancer
08/24
11/24
SGR-3515-101, NCT06463340: Study of SGR-3515 In Participants With Advanced Solid Tumors.

Recruiting
1
52
Canada, US
SGR-3515
Schrödinger, Inc.
Advanced Solid Tumor
10/26
12/26
NCT06551142: A Study of GSK5764227 in Participants With. Advanced Solid Tumors

Recruiting
1
240
Canada, Japan, US, RoW
GSK5764227, Cisplatin, Carboplatin, Atezolizumab, Pembrolizumab, Durvalumab, Fluorouracil, Folinic acid, Cetuximab, Bevacizumab
GlaxoSmithKline
Neoplasms
07/26
03/27
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors

Hourglass Oct 2019 - Mar 2020 : From AMBER trial
Checkmark From AMBER trial at SITC 2018 [screenshot]
Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot]
Checkmark From AMBER trial in combination with TSR-022 at SITC 2018
Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018
Recruiting
1
447
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Tesaro, Inc.
Neoplasms
04/25
04/27
SGNALPV-001, NCT05229900: A Study of SGN-ALPV in Advanced Solid Tumors

Terminated
1
43
Europe, Canada, US
SGN-ALPV
Seagen Inc.
Ovarian Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Gastroesophageal Junction Carcinoma, Uterine Cervical Neoplasms, Testicular Neoplasms
12/23
12/23
NCT04991480: A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Active, not recruiting
1
390
Europe, US
ART4215, Talazoparib, Talzenna, Niraparib, Zejula
Artios Pharma Ltd
Advanced Cancer, Metastatic Cancer, Breast Cancer
03/25
08/25
TOS-358-001, NCT05683418: A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults with Select Solid Tumors

Recruiting
1
241
Europe, US
TOS-358
Totus Medicines
Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, HR+/HER2-negative Breast Cancer
12/25
12/25
NCT06086522: Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors

Recruiting
1
54
US
QN-302
Qualigen Theraputics, Inc., Translational Drug Development
Solid Tumor
12/25
12/26
NCT05753722: A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

Recruiting
1
270
US
PRTH-101, Pembrolizumab
Incendia Therapeutics
Advanced or Metastatic Solid Tumors
09/27
09/27
Abu-Khalaf, Maysa
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
ELU-FRα-1, NCT05001282: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Terminated
1/2
79
US
ELU001, FA-CDC
Elucida Oncology
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
06/24
06/24
NCT03955640: Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences

Active, not recruiting
1
3
US
Olaparib, 763113-22-0, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Hyperthermia Treatment, Clinical Hyperthermia, Diathermy, Hyperthermia, hyperthermia therapy, Questionnaire Administration, Quality-of-Life Assessment, Quality of Life Assessment
Thomas Jefferson University, AstraZeneca
Metastatic Malignant Neoplasm in the Chest Wall, Recurrent Breast Carcinoma
10/22
10/23
Petrylak, Daniel P
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1145
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
FX-909-CLINPRO-1, NCT05929235: A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

Recruiting
1
75
US
FX-909
Flare Therapeutics Inc.
Advanced Solid Tumors Cancer, Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label
09/26
01/27
Dhodapkar, Madhav
NCT04150965: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Active, not recruiting
1/2
14
US
Elotuzumab, pomalidomide, dexamethasone, Empliciti, Anti-LAG-3, BMS-986016, Anti LAG-3, Relatlimab, Anti-LAG-3 + Pomalidimide + Dexamethasone, Anti-LAG-3, Pomalidomide, Dexamethasone, Anti-TIGIT, BMS-986207, Anti-TIGIT + Pomalidimide + Dexamethasone
Multiple Myeloma Research Consortium, Bristol-Myers Squibb, Emory University, Washington University School of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Wake Forest University Health Sciences, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, University of Texas, Hackensack Meridian Health, University of Michigan
Multiple Myeloma, Relapsed Refractory Multiple Myeloma
12/23
12/24
Pomara, Nunzio
APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Enrolling by invitation
3
285
Europe, Canada, US
Experimental: ALZ-801
Alzheon Inc.
Early Alzheimer's Disease
12/25
01/26
NCT04784416: Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)

Recruiting
2
125
US
Active tPBM-2.0, Sham tPBM-2.0, 18F-MK-6240
NYU Langone Health, National Institutes of Health (NIH), Alzheimer's Association, LiteCure LLC
Mild Cognitive Impairment, Alzheimer Disease
10/25
01/26
Foss, Francine M
SGNTGT-001, NCT04254107: A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Terminated
1
132
Europe, Canada, US
SEA-TGT, SGN-TGT, sasanlimab, brentuximab vedotin, Adcetris
Seagen Inc.
Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer
12/23
12/23
Gitelman, Stephen
NCT05743244: Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

Recruiting
2
78
US
Abrocitinib 200 MG Oral Tablet, CIBINQO, Ritlecitinib, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pfizer
Diabetes Mellitus, Type 1
06/26
06/27
TOPPLE T1D, NCT04279613: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

Completed
1
47
US
NNC0361-0041, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novo Nordisk A/S
Type I Diabetes
08/23
04/24
Herold, Kevan
TOPPLE T1D, NCT04279613: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

Completed
1
47
US
NNC0361-0041, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novo Nordisk A/S
Type I Diabetes
08/23
04/24
Nguyen, Trung
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
Kaminski, Naftali
STOP-IPF, NCT04598919: Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis

Active, not recruiting
1/2
49
US
Saracatinab, Placebo
National Jewish Health, Yale University, Icahn School of Medicine at Mount Sinai, AstraZeneca, National Center for Advancing Translational Sciences (NCATS), Baylor University, International Center for Health Outcomes and Innovation Research
Idiopathic Pulmonary Fibrosis (IPF)
09/24
06/25
Verma, Subodh
EMPA-HEART 2, NCT04461041: Empagliflozin and Cardiac Remodelling in People Without Diabetes

Completed
4
169
Canada, RoW
Empagliflozin, Jardiance, Placebo
Unity Health Toronto, Canadian Medical and Surgical Knowledge Translation Research Group, Boehringer Ingelheim, Applied Health Research Centre
Cardiovascular Diseases, Left Ventricular Hypertrophy
07/22
07/22
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active, not recruiting
3
1800
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Cardiovascular Diseases
01/26
02/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
PROLONG-ANG3, NCT05256654: A Study of LY3561774 in Participants With Mixed Dyslipidemia

Completed
2
204
Europe, Canada, Japan, US, RoW
LY3561774, Placebo
Eli Lilly and Company
Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia
03/24
05/24
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Active, not recruiting
2
456
Europe, Canada, Japan, US, RoW
LY3540378, Placebo
Eli Lilly and Company
Heart Failure, Heart Failure With Preserved Ejection Fraction
01/25
01/25
NCT05936151: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Recruiting
2
120
Europe, Canada, US
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Overweight or Obesity, CKD, Type 2 Diabetes
11/25
11/25
Formica, Richard
SAFE KIDNEY II, NCT05769582: Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients

Recruiting
2/3
180
US
Anti-BK polyomavirus (AntiBKV)
Memo Therapeutics AG
BK Viremia; BKV DNAemia
11/24
11/24
NCT03410654: Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.

Completed
1
28
US
Tacrolimus, Extended Release, (Envarsus Xr), Envarsus XR® (TAC XR)
Yale University, Veloxis Pharmaceuticals
Kidney Transplant; Complications
01/24
07/24
Seropian, Stuart
BEXMAB, NCT05428969 / 2021-002104-12: A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

Recruiting
1/2
181
Europe, US
Bexmarilimab, FP-1305, Azacitidine, Venetoclax, Venclyxto®
Faron Pharmaceuticals Ltd, Faron Pharmaceuticals Ltd
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML
04/25
12/25
Petrakis, Ismene
NCT04827056: Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study

Completed
1
10
US
Placebo, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, BXCL501 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg, BXCL501 80µg, Ethanol Infusion, PTSD Reactivity Condition, Alcohol Cue Reactivity
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance, United States Department of Defense, Congressionally Directed Medical Research Programs, RTI International, VA Connecticut Healthcare System, BioXcel Therapeutics Inc, Yale University
Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)
05/23
06/23
NCT06335407: Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study

Not yet recruiting
1
10
US
Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, BXCL501 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg, BXCL501 80µg
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance, United States Department of Defense, Congressionally Directed Medical Research Programs, VA Connecticut Healthcare System, BioXcel Therapeutics Inc, Yale University, RTI International
Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)
09/25
10/25
NCT05948605: EMPOWER AUD Pivotal Trial

Active, not recruiting
N/A
128
US
Empower Neuromodulation System
Theranova, L.L.C.
Alcoholism, Alcohol Abuse, Alcohol Use Disorder
03/25
05/25
Hinchcliff, Monique
CONQUEST, NCT06195072: Platform Clinical Study for Conquering Scleroderma

Recruiting
2
400
US
Amlitelimab, BI 1015550, Placebo
Scleroderma Research Foundation, Inc., Sanofi, Boehringer Ingelheim
Interstitial Lung Disease Due to Systemic Disease, Scleroderma
11/26
11/26
Carpenter, Thomas O
PARADIGHM, NCT01922440: A Registry for Participants With Chronic Hypoparathyroidism

Active, not recruiting
N/A
1339
Europe, Canada, US
No intervention
Takeda, Takeda Development Center Americas, Inc.
Hypoparathyroidism
11/34
11/34
Deshpande, Hari
SUNRISELMS, NCT05269355 / 2022-000073-12: A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

Active, not recruiting
2/3
360
Europe, Canada, US, RoW
Unesbulin, PTC596, Dacarbazine, DTIC, Placebo
PTC Therapeutics, PTC Therapeutics, Inc.
Leiomyosarcoma
06/24
06/24
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
Santin, Alessandro
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
NCT03832361: Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

Recruiting
2
50
US
IMGN853, mirvetuximab soravtansine
Alessandro Santin, ImmunoGen, Inc.
Endometrial Cancer
10/25
10/28
NCT02899793: Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer

Active, not recruiting
2
25
US
Pembrolizumab, MK-3475
Yale University, Merck Sharp & Dohme LLC
Recurrent Endometrial Cancer
10/25
10/25
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Hourglass Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC
Hourglass Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC
Hourglass Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer
Hourglass Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer
Completed
2
79
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IMGN853
AbbVie
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
01/24
12/24
NCT04251416: A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

Recruiting
2
50
US
Sacituzumab Govitecan, IMMU-132
Yale University, Gilead Sciences
Endometrial Carcinoma
12/25
02/26
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
AbbVie
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
05/26
05/26
NCT02491099: A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma

Recruiting
2
50
US
Afatinib, Irreversible Human Epidermal Growth Factor
Yale University, Boehringer Ingelheim
HER2/Neu+ Uterine Serous Carcinoma
07/25
07/25
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation

Active, not recruiting
2
225
Europe, Canada, US
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
11/24
12/26
NCT06028932: A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

Recruiting
2
20
US
Sacituzumab govitecan, IMMU-132
Yale University, Gilead Sciences
Ovarian Carcinoma
11/25
11/27
NCT05838521: A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

Recruiting
2
20
US
Sacituzumab govitecan, Trodelvy
Yale University, Gilead Sciences
Cervical Cancer
06/26
06/28
STRO-002-GM1, NCT03748186: Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

Completed
1
136
Europe, US
STRO-002
Sutro Biopharma, Inc.
Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
06/24
06/24
Schilsky, Michael
GATEWAY, NCT04537377 / 2020-000963-22: A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease

Active, not recruiting
1/2
4
Europe, US
VTX-801
Vivet Therapeutics SAS
Wilson's Disease
12/24
06/29
REASON, NCT05783687: Real World Evidence Study in Subjects With Wilson's Disease

Active, not recruiting
N/A
50
US
NCC-Sp Assay
Orphalan
Wilson Disease
12/25
12/25
Sherwin, Robert
NCT05629741: A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101

Terminated
1
28
US
CMTX-101, Placebo
Clarametyx Biosciences, Inc.
Community-acquired Pneumonia, Bacterial Pneumonia
08/24
08/24
Lampert, Rachel
NCT04496518: Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS)

Active, not recruiting
N/A
2200
Europe, US
Intrinsic Antitachycardia Pacing (iATP) Therapy
Medtronic
Ventricular Tachycardia
01/25
01/27
NCT04489225: Personalized Therapy Study - HFRS (TriageHF) Post Approval Study

Active, not recruiting
N/A
2200
Europe, US
Observational
Medtronic
Heart Failure
01/25
01/27
ASQ, NCT04024943: Personalized Therapy Study - Attain Stability Quad Post-Approval Study

Active, not recruiting
N/A
1092
Europe, US
Quadripolar LV Lead, Medtronic CRT-P, Medtronic CRT-D
Medtronic
Heart Failure
01/27
04/27
Stern, Yaakov
NCT01222351: Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172

Completed
N/A
161
US
BAY 94-9172 (Florbetaben), Florbetaben, Bay 91-9172
New York State Psychiatric Institute, Bayer, National Institute on Aging (NIA)
Late Onset Alzheimer Disease
10/14
10/14
Aruny, John
NCT05616104: FLEX FIRST Registry Research Protocol

Active, not recruiting
N/A
400
US
FLEX Vessel Prep System, Balloon Angioplasty
VentureMed Group Inc.
Arteriovenous Fistula, Arteriovenous Graft, Fistula, Arterial Occlusive Diseases
02/25
08/25
NCT04543539: IN.PACT™ AV Access Post-Approval Study (PAS002)

Active, not recruiting
N/A
240
US
IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort, IN.PACT™ AV Drug Coated Balloon (DCB) - Extended Cohort
Medtronic
Arteriovenous Fistula, Arteriovenous Fistula Stenosis, Arteriovenous Fistula Occlusion, Fistula
02/25
02/29
Antin-Ozerkis, Danielle
STOP-IPF, NCT04598919: Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis

Active, not recruiting
1/2
49
US
Saracatinab, Placebo
National Jewish Health, Yale University, Icahn School of Medicine at Mount Sinai, AstraZeneca, National Center for Advancing Translational Sciences (NCATS), Baylor University, International Center for Health Outcomes and Innovation Research
Idiopathic Pulmonary Fibrosis (IPF)
09/24
06/25
Weinzimer, Stuart A
NCT06449677: Bionic Pancreas in CFRD

Recruiting
3
150
US
iLet Bionic Pancreas System (BP), Usual Care (UC)
Jaeb Center for Health Research, Cystic Fibrosis Foundation, Massachusetts General Hospital, Beta Bionics, Inc.
Cystic Fibrosis-related Diabetes
11/25
03/26
NCT04959552: FSL2 Post Approval Study for Pediatric and Young Adults Patients

Recruiting
N/A
550
US
FreeStyle Libre 2
Abbott Diabetes Care
Diabete Mellitus
12/25
12/25
Lacy, Jill
ASPIRE, NCT05254171: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Recruiting
2/3
600
Europe, US, RoW
SBP-101, ivospemin, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Placebo
Panbela Therapeutics, Inc.
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
08/26
01/27
ARC-8, NCT04104672: A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

Recruiting
1
195
US
AB680, Zimberelimab, AB122, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar
Arcus Biosciences, Inc.
Advanced Pancreatic Cancer
05/27
05/27
Bateman, Randall
DIAN-TU, NCT06384573: Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

Recruiting
3
65
Europe, US, RoW
lecanemab, BAN2401
Washington University School of Medicine, Alzheimer's Association, Eisai Inc.
Alzheimer's Disease, Dementia, Alzheimer's Disease, Familial
11/29
11/29
DIAN-TU, NCT06424236: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Terminated
2/3
73
Europe, US, RoW
Gantenerumab, RO4909832
Washington University School of Medicine, Hoffmann-La Roche, Alzheimer's Association, National Institute on Aging (NIA)
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
10/23
11/23
DIAN-TU, NCT05269394: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Active, not recruiting
2/3
197
Europe, Canada, Japan, US, RoW
E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Alzheimer's Association, National Institute on Aging (NIA), Accelerating Medicines Partnership (AMP), Eisai Inc.
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
04/28
07/28
DIAN-TU, NCT01760005 / 2013-000307-17: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol -001

Checkmark From DIAN-TU trial
Feb 2020 - Feb 2020: From DIAN-TU trial
Checkmark Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Feb 2020 - Feb 2020: Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Checkmark DIAN TU: N=210
More
Recruiting
2/3
490
Europe, Canada, Japan, US, RoW
Gantenerumab, RO4909832, Solanezumab, LY2062430, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Eli Lilly and Company, Hoffmann-La Roche, Alzheimer's Association, National Institute on Aging (NIA), Avid Radiopharmaceuticals, Accelerating Medicines Partnership (AMP), Eisai Inc., Janssen, LP
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
04/28
07/28
McDade, Eric
DIAN-TU-002, NCT06647498: A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Recruiting
2/3
280
Europe, Canada, US, RoW
Remternetug, LY3372993, Matching Placebo (Remternetug)
Washington University School of Medicine, Alzheimer's Association, Eli Lilly and Company, National Institute on Aging (NIA), GHR Foundation, Private Donors
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
03/34
08/34
DIAN-TU, NCT05552157: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Recruiting
2/3
280
Europe, Canada, US, RoW
Remternetug (SC), Matching Placebo (Remternetug)
Washington University School of Medicine, Alzheimer's Association, Eli Lilly and Company, National Institute on Aging (NIA)
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
03/34
08/34
Dahl, Neera K
FALCON, NCT03918447 / 2018-004651-20: A Trial of Bardoxolone Methyl in Patients With ADPKD -

Terminated
3
667
Europe, Japan, US, RoW
Bardoxolone methyl oral capsule, RTA 402, Placebo oral capsule
Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc., REATA PHARMACEUTICALS, INC
Autosomal Dominant Polycystic Kidney, ADPKD
08/23
08/23
Dyck, Christopher H van
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
DIAN-TU-002, NCT06647498: A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Recruiting
2/3
280
Europe, Canada, US, RoW
Remternetug, LY3372993, Matching Placebo (Remternetug)
Washington University School of Medicine, Alzheimer's Association, Eli Lilly and Company, National Institute on Aging (NIA), GHR Foundation, Private Donors
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
03/34
08/34
DIAN-TU, NCT05269394: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Active, not recruiting
2/3
197
Europe, Canada, Japan, US, RoW
E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Alzheimer's Association, National Institute on Aging (NIA), Accelerating Medicines Partnership (AMP), Eisai Inc.
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
04/28
07/28
 

Download Options